INFORMATION DISCLOSURE STATEMENT

Goddard, et al.

App. No

10/063,596

Filed

May 3, 2002

For

SECRETED AND TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC ACIDS

ENCODING THE SAME

Examiner

Wegert, Sandra L.

Art Unit

1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class an envelope addressed to: mail in Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 27, 2005

(Date)

AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 21 references to be considered by the Examiner. Also enclosed are 21 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 27

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record

Customer No. 30,313

(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/063,596
Filing Date	May 3, 2002
First Named Inventor	Goddard, et al.
Art Unit	1647
Examiner	Wegert, Sandra L.
Attorney Docket No.	GNE.3230R1C69

SHEET 1 OF 2

SEP 29 LOW		U.S. PATENT DOCUMENTS				
Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Τ1
	1	WO 97/38085	10-16-1997	California Pacific Medical Center		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	2	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	3	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. <i>Blood</i> , 87(12):5257-5268.	
4	4	ANDERSON, et al. 1997. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis, 18:533-537.	
•	5	CHEN, et al. 2002. Discordant protein and mRNA expression in lung adenocarcinomas. <i>Molecular</i> & Cellular Proteomics 1.4, pp. 304-313.	
	6	FESSLER, et al. 2002. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. <i>The Journal of Biological Chemistry</i> , 277(35):31291-31302.	
	7	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal</i> , 15(16):4392-4401.	
	8	GÖKMEN-POLAR, et al. 2001. Elevated protein kinase C ßII is an early promotive event in colon carcinogenesis. <i>Cancer Research</i> , 61:1375-1381.	
	9	HANASH, S. 2003. Making sense of microarray data to classify cancer. <i>The Pharmacogenomics Journal</i> , 3:308-311.	
	10	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.	
	11	HANCOCK, W. S. 2004. Do we have enough biomarkers? <i>Journal of Proteome Research</i> , 3(4):685.	
	12	HAYNES, et al. 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , 19:1862-1871.	

Examin	er	Sin	nati	ıre
	101	OIG	Hall	416

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/063,596

Filing Date May 3, 2002

First Named Inventor Goddard, et al.

Art Unit 1647

Examiner Wegert, Sandra L.

Multiple sheets used when necessary)
SHEET 2 OF 2

Attorney Docket No. GNE.3230R1C69

SEP 2 9 200

	F. _		
	0	NON PATENT LITERATURE DOCUMENTS	
Learniner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т1
	13	HU, et al. 2003. Analysis of genomic and proteomic data using advanced literature mining. <i>Journal of Proteome Research</i> , 2:405-412.	
	14	JANG, et al. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastatis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> , 15(5):469-483. (Abstract).	
	15	KONOPKA, et al. 1986. Variable expression of the translocated <i>c-abl</i> oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients. <i>Proc. Natl. Acad. Sci. USA</i> , 83:4049-4052.	
	16	OHARA, et al. 2001. Directional cDNA library construction assisted by the <i>in vitro</i> recombination reaction. <i>Nucleic Acids Research</i> , 29(4):e22 p. 1-8.	
	17	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular & Cellular Proteomics</i> , 1:37-45.	
	18	POWELL, et al. 1998. Expression of cytochrome P4502E1 in human liver: Assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics</i> , 8:411-421. (Abstract).	
	19	TOKUNAGA, et al. 2000. Application of quantitative RT-PCR using "TaqMan" technology to evaluate the expression of CK 18 mRNA in various cell lines. <i>J. Exp. Clin. Cancer Res.</i> , 19(3):375-381.	
	20	VALLEJO, et al. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. Biochimie, 82(12):1129-1133. (Abstract).	
•	21	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	

19566**5**8 092705

Examiner Signature

Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.